PHILADELPHIA – Treatment with the personalized cancer vaccine RO7198457 in combination with the PD-L1 inhibitor atezolizumab (Tecentriq) was well...
PHILADELPHIA – In Texas, Hispanic patients with certain blood cancers had lower overall survival than non-Hispanic white patients, and...
Two-day Historic Online Scientific Meeting Featured 102 Oral Presentations and 126 Posters PHILADELPHIA – The American Association for Cancer...
Study also indicated that a lack of ctDNA may signal improved outcomes for patients SAN ANTONIO — The presence...
SAN ANTONIO — A large meta-analysis of breast cancer patients showed that residual cancer burden after neoadjuvant chemotherapy is...
SAN ANTONIO — Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better...
Estrogen alone decreased, while adding progestin increased, breast cancer incidence SAN ANTONIO — Long-term follow-up results from two large,...
SAN ANTONIO — Among women with hormone receptor (HR)-positive, HER2-negative breast cancer with a high clinical risk (determined by tumor...
SAN ANTONIO — The addition of the anti-PD-L1 immunotherapeutic atezolizumab (Tecentriq) to neoadjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) did...
SAN ANTONIO — Breast cancer incidence among postmenopausal women at high risk for developing the disease continued to be...